Engineering Single-Chain Antibody Fragment (scFv) Variants Targeting A Disintegrin and Metalloproteinase-17 (ADAM-17)
Masoud Kalantar, Elham Khorasani Buxton, Korey M. Reid, Donald Bleyl, David M. Leitner, Maryam Raeeszadeh-Sarmazdeh · 2025
Read Engineering Single-Chain Antibody Fragment (scFv) Variants Targeting A Disintegrin and Metalloproteinase-17 (ADAM-17) by Masoud Kalantar, Elham Khorasani Buxton, Korey M. Reid, Donald Bleyl, David M. Leitner, Maryam Raeeszadeh-Sarmazdeh (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12838881.txt.
Description
Masoud Kalantar and co-authors engineer small antibody pieces aimed at a cancer-linked enzyme, in a 2025 study. The enzyme, ADAM-17, also frees a major inflammation signal from cell surfaces. It helps cancer spread and fuels inflammatory disease when it runs too hot. Pills that block it have hit other targets and proved unstable, so antibodies offer a cleaner route. The worry is selectivity: blocking the wrong cousins of the enzyme could do harm.
The team displayed antibody pieces on yeast, sorted the strongest binders by fluorescence, and read their sequences in bulk. That process tuned one stretch of the binding loop that grips the target. The work pinpoints which residues drive tight, selective binding. The authors offer the result as a blueprint for designer antibodies against this enzyme and its relatives.
Catalog record
| CREATOR | Masoud Kalantar, Elham Khorasani Buxton, Korey M. Reid, Donald Bleyl, David M. Leitner, Maryam Raeeszadeh-Sarmazdeh |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |